Does RARE pay dividends?

Ultragenyx (RARE) does not currently pay a regular dividend.

What is RARE's market cap?

Ultragenyx (RARE) has a market capitalization of $2.49B with a current stock price of $25.21.

Ultragenyx (RARE)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$25.21

-0.40 (-1.56%)

Market Cap: $2.49B

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

35%(14/40)

Avg Surprise

-12.98%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.58

Range$-1.25 - $0.75

4 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate Drift

90d ago$-0.95-63.8%

60d ago$-0.95-63.8%

30d ago$-0.95-63.8%

7d ago$0.05+108.0%

Current$-0.58

Revenue Consensus

$183M

Range$168M - $194M

16 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.81

Range$-1.94 - $1.85

5 analysts

Revenue Consensus

$241M

Range$200M - $381M

18 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.81	$-1.94 - $1.85	-	-	5	-	-
Sep 30, 2026Sep 26EST	-	$-0.58	$-1.25 - $0.75	-	-	4	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 4, 2026Reported Aug 4	$-0.90	$-1.27	$-1.48 - $-1.06	+29.13%	Beat	2	0 3 30d	+23.1%
Mar 31, 2026Mar 26 Reported May 5, 2026Reported May 5	$-1.54	$-1.46	$-2.01 - $-0.78	-5.48%	Miss	11	0 2 30d	+1.9%
Dec 31, 2025Dec 25 Reported Feb 12, 2026Reported Feb 12	$-1.29	$-1.17	$-1.76 - $-0.71	-10.26%	Miss	12	2 1 30d	+7.2%
Sep 30, 2025Sep 25 Reported Nov 4, 2025Reported Nov 4	$-1.81	$-1.21	$-1.39 - $-0.98	-49.59%	Miss	12	3 2 30d	-29.3%
Jun 30, 2025Jun 25 Reported Aug 5, 2025Reported Aug 5	$-1.17	$-1.32	$-1.41 - $-1.11	+11.36%	Beat	11	7 1 30d	+23.0%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$-1.57	$-1.64	$-2.41 - $-1.18	+4.27%	Beat	10	0 1 30d	+22.7%
Dec 31, 2024Dec 24 Reported Feb 13, 2025Reported Feb 13	$-1.39	$-1.27	$-1.48 - $-1.01	-9.45%	Miss	11	2 0 30d	+8.6%
Sep 30, 2024Sep 24 Reported Nov 5, 2024Reported Nov 5	$-1.40	$-1.47	$-1.76 - $-0.88	+4.76%	Beat	18	1 0 30d	+37.2%
Jun 30, 2024Jun 24 Reported Aug 1, 2024Reported Aug 1	$-1.52	$-1.63	$-2.13 - $-1.41	+6.75%	Beat	17	2 0 30d	+32.4%
Mar 31, 2024Mar 24 Reported May 2, 2024Reported May 2	$-2.03	$-1.72	$-2.04 - $-1.39	-18.02%	Miss	18	1 0 30d	+12.9%
Dec 31, 2023Dec 23 Reported Feb 15, 2024Reported Feb 15	$-1.52	$-1.61	$-2.45 - $-0.71	+5.59%	Beat	16	1 0 30d	+30.6%
Sep 30, 2023Sep 23 Reported Nov 2, 2023Reported Nov 2	$-2.23	$-2.01	$-2.71 - $-1.55	-10.95%	Miss	15	1 4 30d	+35.9%
Jun 30, 2023Jun 23 Reported Aug 3, 2023Reported Aug 3	$-2.25	$-2.02	$-2.32 - $-1.63	-11.39%	Miss	17	1 0 30d	-6.1%
Mar 31, 2023Mar 23 Reported May 4, 2023Reported May 4	$-2.33	$-1.61	$-2.91 - $-1.55	-44.72%	Miss	17	1 0 30d	-13.1%
Dec 31, 2022Dec 22 Reported Feb 16, 2023Reported Feb 16	$-2.19	$-1.80	$-3.33 - $-1.60	-21.67%	Miss	17	3 0 30d	-41.3%
Sep 30, 2022Sep 22 Reported Nov 2, 2022Reported Nov 2	$-3.48	$-2.40	$-3.04 - $4.63	-45.00%	Miss	16	1 1 30d	-140.0%
Jun 30, 2022Jun 22 Reported Jul 28, 2022Reported Jul 28	$-2.12	$-1.64	$-2.31 - $-1.22	-29.27%	Miss	16	1 0 30d	-57.0%
Mar 31, 2022Mar 22 Reported May 5, 2022Reported May 5	$-2.06	$-1.78	$-2.21 - $-1.45	-15.73%	Miss	16	1 0 30d	-19.8%
Dec 31, 2021Dec 21 Reported Feb 10, 2022Reported Feb 10	$-1.55	$-1.19	$-1.73 - $-0.77	-30.25%	Miss	17	3 1 30d	+2.5%
Sep 30, 2021Sep 21 Reported Nov 2, 2021Reported Nov 2	$-1.45	$-1.10	$-1.83 - $-0.93	-31.82%	Miss	18	No revisions (30d)	-54.3%
Jun 30, 2021Jun 21 Reported Aug 2, 2021Reported Aug 2	$-1.35	$-1.05	$-2.27 - $-0.97	-28.57%	Miss	16	No revisions (30d)	-18.4%
Mar 31, 2021Mar 21 Reported May 4, 2021Reported May 4	$-1.72	$-1.29	$-1.81 - $-0.77	-33.33%	Miss	14	No revisions (30d)	+15.7%
Dec 31, 2020Dec 20 Reported Feb 11, 2021Reported Feb 11	$-1.59	$-1.14	$-1.91 - $-0.69	-39.47%	Miss	16	3 0 30d	+1.9%
Sep 30, 2020Sep 20 Reported Oct 27, 2020Reported Oct 27	$-0.94	$-1.06	$-1.75 - $-0.53	+11.32%	Beat	15	1 0 30d	+53.0%
Jun 30, 2020Jun 20 Reported Jul 30, 2020Reported Jul 30	$-1.14	$-1.72	$-1.79 - $-0.82	+33.72%	Beat	16	No revisions (30d)	+40.0%
Mar 31, 2020Mar 20 Reported May 6, 2020Reported May 6	$-2.04	$-1.68	$-2.45 - $-1.38	-21.43%	Miss	16	1 0 30d	-12.1%
Dec 31, 2019Dec 19 Reported Feb 13, 2020Reported Feb 13	$-1.62	$-1.53	$-1.98 - $-1.46	-5.88%	Miss	16	3 0 30d	+6.4%
Sep 30, 2019Sep 19 Reported Nov 5, 2019Reported Nov 5	$-2.00	$-1.55	$-1.97 - $-1.49	-29.03%	Miss	16	1 0 30d	-14.9%
Jun 30, 2019Jun 19 Reported Aug 1, 2019Reported Aug 1	$-1.90	$-1.59	$-1.81 - $-1.45	-19.50%	Miss	16	2 0 30d	-1.6%
Mar 31, 2019Mar 19 Reported May 6, 2019Reported May 6	$-1.82	$-1.67	$-1.90 - $-1.53	-8.98%	Miss	16	1 0 30d	+12.1%
Dec 31, 2018Dec 18 Reported Feb 19, 2019Reported Feb 19	$-1.73	$-1.79	$-2.28 - $-1.26	+3.35%	Beat	16	No revisions (30d)	+8.5%
Sep 30, 2018Sep 18 Reported Nov 5, 2018Reported Nov 5	$-1.74	$-1.99	$-2.15 - $-1.81	+12.56%	Beat	17	2 0 30d	+7.0%
Jun 30, 2018Jun 18 Reported Aug 2, 2018Reported Aug 2	$-1.87	$-2.13	$-2.20 - $-1.92	+12.21%	Beat	17	1 0 30d	-8.7%
Mar 31, 2018Mar 18 Reported May 7, 2018Reported May 7	$-2.07	$-0.87	$-2.20 - $3.83	-137.93%	Miss	17	4 0 30d	-27.0%
Dec 31, 2017Dec 17 Reported Feb 20, 2018Reported Feb 20	$-1.89	$-1.99	$-2.26 - $-1.73	+5.03%	Beat	13	No revisions (30d)	-8.0%
Sep 30, 2017Sep 17 Reported Nov 2, 2017Reported Nov 2	$-1.87	$-1.87	$-1.98 - $-1.67	+0.00%	Beat	16	No revisions (30d)	-14.0%
Jun 30, 2017Jun 17 Reported Jul 27, 2017Reported Jul 27	$-1.72	$-1.71	$-1.83 - $-1.59	-0.58%	Miss	14	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported May 4, 2017Reported May 4	$-1.63	$-1.71	-	+4.68%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Feb 16, 2017Reported Feb 16	$-1.75	$-1.73	-	-1.16%	Miss	-	-	-
Sep 30, 2016Sep 16 Reported Nov 7, 2016Reported Nov 7	$-1.64	$-1.57	-	-4.46%	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-4.55	EV/EBITDA	-6.46x
Price/FCF	-5.25x	FCF Yield	-19.05%
Profitability
Profit Margin	-81.70%	Operating Margin	-35.00%
ROE	-608.00%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	-6.91x
Current Ratio	1.73x	Quick Ratio	1.56x
Trading Statistics
Beta	0.31	Avg Volume	2.13M
52-Week High	$39.89	52-Week Low	$18.29

Technical Indicators Dashboard

Moving Averages

SMA 10$25.86

SMA 20$26.03

SMA 50$28.38

SMA 200$26.24

EMA 10$25.90

EMA 20$26.22

EMA 50$26.74

EMA 200$27.23

MACD

Line: -0.47Signal: -0.53Hist: 0.06

ADX

ADX: 17.6+DI: 21.2-DI: 20.1

Aroon & PSAR

Aroon Up72.0

Aroon Down20.0

PSAR$28.44

Bollinger Bands

Upper Band$27.16

Lower Band$24.91

%B Position866%(Upper)

Band Width0.13

RSI (14-Day)

Neutral

40.9

Momentum Oscillators

Stoch %K22.5

Stoch %D31.9

Williams %R-87.3

ROC (10d)-3.5%

Momentum-0.92

CCI (20d)-165.3

MFI (14d)24.3

Volatility Measures

ATR (14d)$1.34(5.3%)

StdDev (20d)0.56

Hist Vol36.5%(Moderate)

Volume Flow

VWAP$25.28

OBV-12.4M

AD Line10.1M

CMF (20d)-0.113

Volume Metrics

Avg Vol (20d)2.1M

Vol Ratio0.9x

VWMA (20d)$25.99

Pivot Points

R3$27.80

R2$27.26

R1$26.44

Pivot Point$25.90

S1$25.08

S2$24.54

S3$23.72

Advanced Oscillators

TSI-11.92

Ultimate Osc44.8

KST-82.51

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$214.00M	$136.00M	$207.28M	$159.93M	$167.00M	$139.00M	$164.65M	$139.49M	$147.03M	$108.83M	$127.14M	$98.05M
Cost of Revenue	$34.00M	$30.00M	$29.34M	$27.99M	$23.00M	$29.00M	$17.17M	$21.02M	$21.28M	$17.53M	$11.84M	$10.99M
Gross Profit	$180.00M	$106.00M	$177.93M	$131.94M	$144.00M	$110.00M	$147.48M	$118.47M	$125.75M	$91.30M	$115.30M	$87.06M

Operating Expenses	$255.00M	$275.00M	$291.22M	$302.83M	$252.00M	$253.00M	$269.79M	$250.46M	$242.11M	$256.65M	$237.14M	$232.16M
R&D	$167.00M	$187.00M	$203.28M	$216.21M	$165.00M	$166.00M	$187.90M	$170.11M	$161.50M	$178.49M	$160.11M	$157.25M
SG&A	$88.00M	$88.00M	$87.94M	$86.62M	$87.00M	$87.00M	$81.89M	$80.35M	$80.60M	$78.16M	$77.03M	$74.92M
Operating Income	$-75,000,000	$-169,000,000	$-113,283,000	$-170,890,000	$-108,000,000	$-143,000,000	$-122,305,000	$-131,987,000	$-116,361,000	$-165,347,000	$-121,841,000	$-145,097,000

Interest Income	$5.00M	$6.00M	$6.00M	$6.54M	$6.00M	$7.00M	$9.61M	$11.41M	$3.41M	$12.57M	$10.36M	$4.46M
Interest Expense	$22.00M	$21.00M	$19.47M	$14.15M	$14.00M	$14.00M	$15.48M	$15.71M	$15.96M	$15.85M	$17.32M	$17.66M
Income Before Tax	$-91,000,000	$-184,000,000	$-127,686,000	$-179,540,000	$-114,000,000	$-150,000,000	$-132,818,000	$-133,213,000	$-130,740,000	$-170,229,000	$-127,428,000	$-158,999,000
Income Tax Expense	$1.00M	$1.00M	$870,000	$873,000	$1.00M	$1.00M	$384,000	$303,000	$858,000	$455,000	$-3,877,000	$650,000

Net Income	$-92,000,000	$-185,000,000	$-128,556,000	$-180,413,000	$-115,000,000	$-151,000,000	$-133,202,000	$-133,516,000	$-131,598,000	$-170,684,000	$-123,551,000	$-159,649,000

EBITDA	$-66,000,000	$-162,000,000	$-105,948,000	$-164,031,000	$-98,000,000	$-136,000,000	$-120,594,000	$-123,268,000	$-112,275,000	$-161,863,000	$-116,355,000	$-141,286,000
EBIT	$-74,000,000	$-169,000,000	$-114,217,000	$-171,933,000	$-106,000,000	$-143,000,000	$-126,948,000	$-128,910,000	$-118,190,000	$-166,952,000	$-120,461,000	$-145,796,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about RARE

News

Ultragenyx Delivers First Gene Therapy FDA Approval for GSDIa

Ultragenyx Pharmaceutical Inc. (RARE:NASDAQ) has received FDA accelerated approval for GENGLYCOS, its first gene therapy, targeting Glycogen Storage Disease Type Ia (GSDIa) in patients aged eight and older. This approval marks a significant shift from symptom management to addressing the underlying genetic cause of the disease, which affects 1,500 to 2,500 patients in the U.S. The approval, based on Phase 3 data showing reduced cornstarch dependency, has led to increased price targets from analysts, with Ultragenyx expecting a commercial launch within 30-60 days at a wholesale cost of $2.7 million.

Streetwise Reports•Aug 26, 2026 10:29 AM8/26/26•

Bullish

BlackRock Inc. Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARE

BlackRock Inc. has acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, purchasing over 10.65 million shares valued at approximately $355.7 million, representing about 10.82% of the company. Other institutional investors have also adjusted their holdings, while company insiders have sold a total of 8,552 shares worth $207,455. Analysts have updated price targets for RARE, with the stock currently holding a "Moderate Buy" rating and an average price target of $59.22.

MarketBeat•Aug 26, 2026 8:40 AM8/26/26•

Bullish

Algert Global LLC Reduces Position in Ultragenyx Pharmaceutical Inc. $RARE

Algert Global LLC decreased its stake in Ultragenyx Pharmaceutical Inc. by 9.0% in the second quarter, now owning 389,964 shares worth $13.02 million. Other institutional investors, such as Parallel Advisors LLC and Leonteq Securities AG, increased their holdings. Insider activity also saw directors and executives selling shares, though insiders still collectively own 5.20% of the company's stock.

MarketBeat•Aug 26, 2026 7:40 AM8/26/26•

Neutral

Ultragenyx Pharmaceutical Grants Inducement Restricted Stock Units to 23 New Employees

Ultragenyx Pharmaceutical has granted 45,984 restricted stock units to 23 new non-executive employees as an employment inducement, in accordance with Nasdaq regulations. These units will vest over four years, with 25% vesting annually, provided the employees remain continuously employed. This move aims to attract and retain talent in the biopharmaceutical sector, though it could lead to concerns about equity dilution among existing shareholders.

Quiver Quantitative•Aug 25, 2026 8:40 PM8/25/26•

Neutral

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. granted 45,984 restricted stock units to 23 newly hired non-executive officers. This inducement award, approved by the compensation committee, vests over four years and is in accordance with Nasdaq Listing Rule 5635(c)(4). Ultragenyx is a biopharmaceutical company focused on rare and ultra-rare genetic diseases.

Yahoo Finance•Aug 25, 2026 8:30 PM8/25/26•

Neutral

Frequently Asked Questions About RARE

Does RARE pay dividends?: Ultragenyx (RARE) does not currently pay a regular dividend.
What is RARE's market cap?: Ultragenyx (RARE) has a market capitalization of $2.49B with a current stock price of $25.21.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In